A survey amongst the participants of the Paraneoplastic Neurological Antibody Scheme, registered with United Kingdom National External Quality Assessment Service (UK NEQAS), across the UK, continental Europe and non- European countries examined various factors involved in the laboratory diagnostic methodologies, timely provision of results and a snapshot of External Quality Assessment (EQA) performance to ascertain the level of harmonisation amongst participating laboratories. Despite variations in some aspects of the analytical methods there appears to be a good agreement in the outcome of the results as demonstrated by the EQA performance.